Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 3, 1999, Pages 735-741

  Ciernik, Ilja F ^a   Romero, Pedro ^a   Berzofsky, Jay A ^b   Carbone, David P ^c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cellular immunity; Mutant p53; Radiation; T cell epitopes; Tumor immunogenicity; Tumor vaccine

Indexed keywords

EPITOPE; PROTEIN P53; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN 3T3; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; IONIZING RADIATION; MASTOCYTOMA; MOUSE; MUTANT; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SARCOMA CELL; T LYMPHOCYTE; TUMOR IMMUNOLOGY;

3T3 CELLS; ANIMALS; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; FEMALE; GENES, P53; HUMANS; IMMUNITY, CELLULAR; MAST-CELL SARCOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; POINT MUTATION; RADIOBIOLOGY; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032825507     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00226-6     Document Type: Article

References (29)

1. Takahashi T., Nau M.M., Chiba I., et al. p53 A frequent target for genetic abnormalities in lung cancer . Science. 246:1989;491-494.
2. Osborne R.J., Merlo G.R., Mitsudomi T., et al. Mutations in the p53 gene in primary human breast cancers. Cancer Res. 51:1991;6194-6198.
3. Hollstein M.C., Metcalf R.A., Welsh J.A., et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA. 87:1990;9958-9961.
4. Takahashi T., Carbone D., Takahashi T., et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 52:1992;2340-2343.
5. Townsend A., Ohlën C., Foster L., et al. A mutant cell in which association of class I heavy and light chains is induced by viral peptides. Cold Spring Harb Symp Quant Biol. 1:1989;299-308.
6. Moudgil K.D., Sercarz E.E. Dominant determinants in hen eggwhite lysozyme correspond to the cryptic determinants within its self-homologue, mouse lysozyme Implications in shaping of the T cell repertoire and autoimmunity . J Exp Med. 178:1993;2131-2138.
7. Schlichtholz B., Legros Y., Gillet D., et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52:1992;6380-6384.
8. Chen L., Thomas E.K., Hu S.-L., et al. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA. 88:1991;110-114.
9. Kahn M., Sugawara H., McGowan P., et al. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol. 146:1991;3235-3241.
10. Rosenberg S. The immunotherapy and gene therapy of cancer. J Clin Oncol. 10:1992;180-199.
11. Kanost D., Basten A., McCluskey J. Threshold detection of self-antigen/MHC class II complex formed in vivo Constitutive presentation of an immunodominant epitope of hen egg lysozyme (HEL) in HEL-transgenic mice . Int Immunol. 5:1993;893-902.
12. Brooks A.G., McCluskey J. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmatic reticulum of the antigen presenting cells. J Immunol. 150:1993;3690-3697.
13. Speiser D.E., Miranda R., Zakarian A., et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells Implications for immunotherapy . J Exp Med. 186:1997;645-653.
14. Chiba I., Takahashi T., Nau M.M., et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene. 5:1990;1603-1610.
15. Takahashi H., Houghten R., Putney S., et al. Structural requirements for class-I MHC molecule-mediated antigen presentation and cytotoxic T-cell recognition of an immunodominant determinant of the HIV envelope protein. J Exp Med. 170:1989;2023-2035.
16. Yanuck M., Carbone D.P., Pendleton C.D., et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells. Cancer Res. 53:1993;3257-3261.
17. Takahashi H., Nakagawa Y., Yokomuro K., et al. Induction of CD8+ CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int Immunol. 5:1993;849-857.
18. Ciernik I.F., Berzofsky J.A., Carbone D.P. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma. 14:1995;139-142.
19. Houbiers J., Nijman H., van der Burg S., et al. In vitro induction of human cytotoxic T lymphocyte response against peptides of mutant and wild-type p53. Eur J Immunol. 23:1993;2072-2077.
20. Noguchi Y., Chen Y.-T., Old L.J. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA. 91:1994;3171-3175.
21. Ciernik I.F., Berzofsky J.A., Carbone D.P. Human lung cancer cells process and present endogenously expressing mutant p53 and are lysed by mutant-specific CTL. Clin Cancer Res. 2:1996;877-882.
22. Lee C.T., Ciernik I.F., Wu S., et al. Increased immunogenicity of tumors bearing mutant p53 and epitopes after transduction of B7-1 via recombinant adenovirus. Cancer Gene Ther. 3:1996;238-244.
23. Gorelik E., Begovic M., Duty I., et al. Effect of ultraviolet irradiation on MCA102 tumor cell immunogenecity and sensitivity to tumor necrosis factor. Cancer Res. 51:1991;1521-1528.
24. Gasparro F.P., Malane M.S., Maxwell V.M., et al. The treatment of mastocytoma cells with 8-methoxypsoralen and long-wavelength ultraviolet radiation enhances cellular immunogenecity Preliminary results . Photochem Photobiol. 58:1993;682-688.
25. Mevorach D., Zhou J., Song X., et al. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med. 188:1998;387-392.
26. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89.
27. Gabrilovich D.I., Ciernik I.F., Carbone D.P. Dendritic cells in anti-tumor immune response Defective presentation in tumor-bearing host . Cell Immunol. 170:1996;101-110.
28. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., Carbone D.P. Decreased antigen presentation by dendritic cells from patients with breast cancer. Clin Cancer Res. 3:1997;483-490.
29. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1996;1096-1103. [published erratum in Nat Med 1996;2:1267].